Skip to content
Alkasolv Uractiv

 Alkasolv Uractiv Sachets

Short description

Alkasolv Uractiv® has the effect of maintaining the hydro-electrolytic balance and correcting the urinary pH in
people prone to kidney stones.


For people with a tendency to form urinary stones.
For people who have followed a lithotripsy procedure.
For people with excess uric acid.


Alkasolv Uractiv is an effective long-term solution for preventing the recurrence of kidney stones by controlling the elimination of calcium in the urine and the balance of the urinary pH at a value that prevents the precipitation of calcium salts from the urine in the form of stones.
Alkasolv Uractiv, sachets do not contain sodium (contains potassium citrate) and therefore can be safely administered to patients with hypertension.
Alkasolv Uractiv sachets contain sucralose, a sweetener with zero calories and that’s why it can be safely administered to diabetic patients.


1 Sachet of Alkasolv Uractiv contains 2162 mg (20mEq) potassium citrate, 827.2 mg (11mEq) magnesium citrate, 25 mg Pyridoxine, acidity regulator (citric acid), orange flavor, anticaking agent (silicon dioxide), sweetener (sucralose).

Dosage and administration

-The recommended dose is one to two sachets daily split into 2 administrations, one in the morning and one in the evening.
Dissolve the content of each sachet in 150-300 ml water.
It is recommended to take this product during or 30 minutes after a meal. With medical advice, the dose can be adjusted.
The product contains sucralose, a non-caloric sweetener; therefore it can be administered safely in diabetic patients.


-Read the package leaflet before use.
-Keep out of the reach and sight of children.
-Store below 25°C, in the original packaging.
-Do not use after the expiry date stated on the package.
-The safety of this product administered during pregnancy was not established.


Concomitant administration of Alkasolv Uractiv and potassium-saving diuretics is not recommended.


-Renal insufficiency (glomerular filtration rate of less than 0.7 mL/kg/min.), because of the danger of soft tissue calcification and increased risk for the development of hyperkalemia.

Patients with active urinary tract infection (with urea-splitting or other organisms, in association with either calcium or struvite stones). The ability of Alkasolv to increase urinary citrate may be attenuated by bacterial enzymatic degradation of citrate.

Patients with hyperkalemia (or who have conditions predisposing them to hyperkalemia), as a further rise in serum potassium concentration may produce cardiac arrest. Such conditions include: chronic renal failure, uncontrolled diabetes mellitus, acute dehydration, strenuous physical exercise in unconditioned individuals, adynamia episodica hereditaria, extensive tissue breakdown as in severe burns, or the administration of a potassium sparing agent (such as trimaterene, spironolactone or amiloride).

Patients with peptic ulcer disease because of its ulcerogenic potential.

-Patients with Uncontrolled diabetes, chronic cardiac deficiency (CCD) and Patients with sever diarrhea.

-Patients with high magnesium, and low sodium in the blood.

-Patients with hypersensitivity to any of the ingredients.

-Potassium-sparing diuretic (such as trimaterene, spironolactone or amiloride) should be avoided

Alkasolv should be given to a pregnant woman only if clearly needed


Cardboard box containing 30 sachets.

Frequently Asked Question

Copyright 2019 © Pristol Pharmaceuticals® is a registered trademark protected by the United States Patent and Trademark Office (USPTO).